Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.
View/ Open
Date
2022-06-21ICR Author
Author
Acs, B
Leung, SCY
Kidwell, KM
Arun, I
Augulis, R
Badve, SS
Bai, Y
Bane, AL
Bartlett, JMS
Bayani, J
Bigras, G
Blank, A
Buikema, H
Chang, MC
Dietz, RL
Dodson, A
Fineberg, S
Focke, CM
Gao, D
Gown, AM
Gutierrez, C
Hartman, J
Kos, Z
Lænkholm, A-V
Laurinavicius, A
Levenson, RM
Mahboubi-Ardakani, R
Mastropasqua, MG
Nofech-Mozes, S
Osborne, CK
Penault-Llorca, FM
Piper, T
Quintayo, MA
Rau, TT
Reinhard, S
Robertson, S
Salgado, R
Sugie, T
van der Vegt, B
Viale, G
Zabaglo, LA
Hayes, DF
Dowsett, M
Nielsen, TO
Rimm, DL
International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG)
Type
Journal Article
Metadata
Show full item recordAbstract
Ki67 has potential clinical importance in breast cancer but has yet to see broad acceptance due to inter-laboratory variability. Here we tested an open source and calibrated automated digital image analysis (DIA) platform to: (i) investigate the comparability of Ki67 measurement across corresponding core biopsy and resection specimen cases, and (ii) assess section to section differences in Ki67 scoring. Two sets of 60 previously stained slides containing 30 core-cut biopsy and 30 corresponding resection specimens from 30 estrogen receptor-positive breast cancer patients were sent to 17 participating labs for automated assessment of average Ki67 expression. The blocks were centrally cut and immunohistochemically (IHC) stained for Ki67 (MIB-1 antibody). The QuPath platform was used to evaluate tumoral Ki67 expression. Calibration of the DIA method was performed as in published studies. A guideline for building an automated Ki67 scoring algorithm was sent to participating labs. Very high correlation and no systematic error (p = 0.08) was found between consecutive Ki67 IHC sections. Ki67 scores were higher for core biopsy slides compared to paired whole sections from resections (p ≤ 0.001; median difference: 5.31%). The systematic discrepancy between core biopsy and corresponding whole sections was likely due to pre-analytical factors (tissue handling, fixation). Therefore, Ki67 IHC should be tested on core biopsy samples to best reflect the biological status of the tumor.
Collections
Subject
International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG)
Research team
Endocrinology
Language
eng
Date accepted
2022-05-05
License start date
2022-06-21
Citation
Modern Pathology, 2022,
Publisher
Springer Science and Business Media LLC
Except where otherwise noted, this item's license is described
as
http://creativecommons.org/licenses/by/4.0/
Related items
Showing items related by title, author, creator and subject.
-
Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration.
Leung, SCY; Nielsen, TO; Zabaglo, LA; Arun, I; Badve, SS; et al. (2019-08)Aims The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential uses in breast cancer, but an unacceptable level of interlaboratory variability has hampered its clinical utility. The ... -
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
Malorni, L; Tyekucheva, S; Hilbers, FS; Ignatiadis, M; Neven, P; et al. (ELSEVIER SCI LTD, 2022-03-01)BACKGROUND: Biomarkers for cyclin-dependent kinase 4/6 inhibitors, such as palbociclib, for patients with hormone receptor-positive/HER2-negative metastatic breast cancer are lacking. Thymidine kinase is a proliferation ... -
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
Lawrenson, K; Kar, S; McCue, K; Kuchenbaeker, K; Michailidou, K; et al. (NATURE PORTFOLIO, 2016-09-07)A locus at 19p13 is associated with breast cancer (BC) and ovarian cancer (OC) risk. Here we analyse 438 SNPs in this region in 46,451 BC and 15,438 OC cases, 15,252 BRCA1 mutation carriers and 73,444 controls and identify ...